ZA9710186B - Process for substituted pyridines - Google Patents

Process for substituted pyridines

Info

Publication number
ZA9710186B
ZA9710186B ZA9710186A ZA9710186A ZA9710186B ZA 9710186 B ZA9710186 B ZA 9710186B ZA 9710186 A ZA9710186 A ZA 9710186A ZA 9710186 A ZA9710186 A ZA 9710186A ZA 9710186 B ZA9710186 B ZA 9710186B
Authority
ZA
South Africa
Prior art keywords
substituted pyridines
pyridines
substituted
Prior art date
Application number
ZA9710186A
Other languages
English (en)
Inventor
Keith Michael De Vries
Robert Lee Dow
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA9710186B publication Critical patent/ZA9710186B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9710186A 1996-11-14 1997-11-12 Process for substituted pyridines ZA9710186B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14

Publications (1)

Publication Number Publication Date
ZA9710186B true ZA9710186B (en) 1999-05-12

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710186A ZA9710186B (en) 1996-11-14 1997-11-12 Process for substituted pyridines

Country Status (32)

Country Link
US (1) US6291489B1 (fr)
EP (1) EP0938476B1 (fr)
JP (1) JP3510635B2 (fr)
KR (1) KR20000053314A (fr)
CN (1) CN1237160A (fr)
AP (1) AP805A (fr)
AR (1) AR010584A1 (fr)
AT (1) ATE319687T1 (fr)
AU (1) AU4634697A (fr)
BG (1) BG103393A (fr)
BR (1) BR9712951A (fr)
CA (1) CA2270386C (fr)
CO (1) CO4930261A1 (fr)
DE (1) DE69735433D1 (fr)
EA (1) EA199900375A1 (fr)
GT (1) GT199700118A (fr)
HR (1) HRP970612A2 (fr)
ID (1) ID18898A (fr)
IL (1) IL129688A0 (fr)
IS (1) IS5029A (fr)
MA (1) MA24401A1 (fr)
MY (1) MY132507A (fr)
NO (1) NO992296D0 (fr)
OA (1) OA11044A (fr)
PA (1) PA8441401A1 (fr)
PE (1) PE10299A1 (fr)
TN (1) TNSN97172A1 (fr)
TR (1) TR199901063T2 (fr)
UY (1) UY24774A1 (fr)
WO (1) WO1998021184A1 (fr)
YU (1) YU22099A (fr)
ZA (1) ZA9710186B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052892A2 (fr) * 1998-04-08 1999-10-21 Novartis Ag Nouveaux herbicides
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
EP1153919A4 (fr) 1999-02-16 2002-10-02 Kaneka Corp Derives d'acetylpyridine substituee et procede de preparation d'intermediaires pour agoniste du recepteur adrenergique beta3 optiquement actif, faisant appel a ces derives
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
ES2228413T3 (es) * 1999-07-23 2005-04-16 Pfizer Products Inc. Productos intermedios y un procedimiento para producir agonistas de receptores beta-adrenergicos.
JPWO2003033468A1 (ja) * 2001-10-17 2005-02-03 株式会社カネカ (S)−α−ハロメチルピリジンメタノール誘導体の製造方法
MXPA04008298A (es) 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
AU2003209527A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
EP1424079A1 (fr) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
CA2523253C (fr) 2003-05-09 2010-06-22 F. Hoffmann-La Roche Ag Methyle indoles et methyle pyrrolopyridines servant d'agonistes du recepteur adrenergique alpha-1
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
CN102137858B (zh) 2008-05-23 2014-07-23 潘米拉制药有限责任公司 5-脂氧合酶-活化蛋白抑制剂
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
US5767133A (en) * 1993-06-14 1998-06-16 Pfizer Inc. Secondary amines as antidiabetic and antiobesity agents
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
CA2220538A1 (fr) * 1995-05-10 1996-11-14 Pfizer Inc. Agonistes du recepteur .beta.-adrenergique
EP0824519A1 (fr) 1995-05-10 1998-02-25 Pfizer Inc. Agonistes du recepteur beta-adrenergique

Also Published As

Publication number Publication date
EP0938476A1 (fr) 1999-09-01
PE10299A1 (es) 1999-02-10
CA2270386C (fr) 2004-08-03
AP805A (en) 2000-01-28
CN1237160A (zh) 1999-12-01
ID18898A (id) 1998-05-20
BG103393A (en) 2000-07-31
IS5029A (is) 1999-04-16
GT199700118A (es) 1999-05-05
US6291489B1 (en) 2001-09-18
IL129688A0 (en) 2000-02-29
PA8441401A1 (es) 2000-05-24
BR9712951A (pt) 1999-12-07
WO1998021184A1 (fr) 1998-05-22
MA24401A1 (fr) 1998-07-01
ATE319687T1 (de) 2006-03-15
TR199901063T2 (xx) 1999-08-23
HRP970612A2 (en) 1998-08-31
TNSN97172A1 (fr) 2005-03-15
KR20000053314A (ko) 2000-08-25
JP2000504347A (ja) 2000-04-11
UY24774A1 (es) 1998-05-05
AP9701147A0 (en) 1998-01-31
NO992296L (no) 1999-05-12
EP0938476B1 (fr) 2006-03-08
AR010584A1 (es) 2000-06-28
JP3510635B2 (ja) 2004-03-29
MY132507A (en) 2007-10-31
CA2270386A1 (fr) 1998-05-22
YU22099A (sh) 2001-09-28
CO4930261A1 (es) 2000-06-27
OA11044A (en) 2002-02-20
EA199900375A1 (ru) 1999-12-29
NO992296D0 (no) 1999-05-12
AU4634697A (en) 1998-06-03
DE69735433D1 (de) 2006-05-04

Similar Documents

Publication Publication Date Title
HRP970330A2 (en) Cycloalkano pyridines
GB9616573D0 (en) Process
GB9626317D0 (en) Process
GB9609441D0 (en) Process
SG46782A1 (en) Bicyclic-fused pyridines
GB9618952D0 (en) Process
EP0880388A4 (fr) Procede d'etherification-hydrogenation
AP9701147A0 (en) Process for substituted pyridines
IL122454A0 (en) Process for forming bubble-pack
GB9602046D0 (en) Process
GB2319771B (en) Process
GB2317178B (en) Process for preparing 1-chloromethylsilatrane
GB9626570D0 (en) Process for making benzisothiazolin-3-ones
GB9619076D0 (en) Process
GB9618835D0 (en) Process
GB2316403B (en) Process
GB9617658D0 (en) Process
GB9618926D0 (en) Cable-making process
HUP9903692A3 (en) Process for making dihydropyrimidinones
GB9616417D0 (en) Process
GB9603385D0 (en) Process
GB9616451D0 (en) Process
GB9616220D0 (en) Process
GB9616418D0 (en) Process
GB9610899D0 (en) Process